CD70 and glioblastoma: The results of univariate Cox analysis showed that increased expression of CD276 (HR 1.47, 95% confidence interval (CI) 1.10–1.97, p = 0.011), TNFRSF14 (HR 1.39, 95% CI 1.09–1.78, p = 0.009), TNFSF14 (HR 1.29, 95% CI 1.07–1.55, p = 0.007), TNFRSF9 (HR 1.60, 95% CI 1.11–2.31, p = 0.013), TNFSF4 (HR 1.48, 95% CI 1.20–1.84, p < 0.001), CD70 (HR 1.17, 95% CI 1.02–1.34, p = 0.025), CD40 (HR 1.39, 95% CI 1.07–1.79, p = 0.013), TNFRSF18 (HR 1.34, 95% CI 1.10–1.63, p = 0.003), and CD96 (HR 1.59, 95% CI 1.11–2.28, p = 0.012) were associated with poor prognoses of glioblastoma (Fig. 1B).